Malignant Pleural mesothelioma is a relatively rare but aggressive form of cancer with very poor prognosis. Platinum-based chemotherapy has been the only therapeutic option in first-line. Currently, the efficacy of second-line therapy remains unproven and is a major unmet need. The diagnostic markers too lack specificity and are yet not effective to detect mesothelioma in early stages.
This infographic highlights the types of pleural mesothelioma, current clinical research, biomarkers and future outlook.
Mesothelioma, considered as a rare and occupational related cancer, is likely to become more common due to increasing exposure to Asbestos. Several countries are yet to see the peak incidence, whereas in some countries it is misdiagnosed or under reported. This infographic attempts to provide the basic statistics around Mesothelioma to understand the impact of this disease on an individual and country level.
One size no longer fits all! Pharmaceutical companies are finally moving towards ‘beyond the pill’ strategy to deliver patient-centric outcomes. Today, companies are developing and providing tailored solutions either in-house or in collaborations to implement technology solutions that will ultimately improve health outcomes and foster stronger relationships between all stakeholders.
From Laboratory Bench to Bedside: the process of developing a new medicine is a complex, time consuming and costly affair. It takes between 10-12 years to move a potential drug from concept to market and can cost the pharmaceutical industry around $2.5B including cost of failures.
There is no doubt that VKAs (Warfarin) have been used since over 50 years for the management of stroke prevention in Non-Valvular Atrial Fibrillation and Venous Thromboembolism. However, the emergence of non-vitamin K oral anticoagulants such as Pradaxa, Xarelto, Eliquis and Lixiana have changed the landscape of thromboprophylaxis.